Highlight
- Vibration-controlled transient elastography (VCTE) shows prognostic performance comparable to liver biopsy histology for predicting liver-related events in MASLD.
- Among 3532 MASLD patients, both liver stiffness measurement (LSM) and histology yielded similar 5-year AUROC metrics for liver-related events.
- Noninvasive LSM by VCTE may serve as an alternative surrogate endpoint in clinical trials, potentially reducing reliance on invasive biopsies.
Study Background and Disease Burden
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), represents a spectrum of liver disorders characterized by hepatic steatosis in the context of metabolic dysfunction such as obesity, diabetes, and dyslipidemia. MASLD is a leading cause of chronic liver disease worldwide, imposing a significant burden on healthcare systems due to its high prevalence and risk of progression to advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
The identification of patients at risk of liver-related events (LREs) such as hepatic decompensation, liver transplantation, or liver-related mortality is essential for risk stratification, management decisions, and enrollment in clinical trials. While histological assessment via liver biopsy remains the gold standard for staging fibrosis, it is invasive, costly, and prone to sampling variability. Noninvasive modalities like vibration-controlled transient elastography (VCTE) measuring liver stiffness provide an attractive alternative, but comparative prognostic data against histology in MASLD have been limited.
Study Design
This multicenter prospective cohort study analyzed data from 3532 patients with MASLD who underwent both vibration-controlled transient elastography (VCTE) to measure liver stiffness and liver biopsy. The mean patient age was 51.9 years, with a male predominance (57.3%). Baseline liver stiffness measurement (LSM) and histological fibrosis stage were assessed concurrently, enabling a head-to-head comparison of prognostic accuracy.
The primary endpoint was the occurrence of liver-related events (LREs), encompassing hepatic decompensation, liver transplantation, or liver-related death. Secondary endpoints included the separate analysis of hepatocellular carcinoma (HCC) development and hepatic decompensation rates. Median follow-up was 56.6 months, allowing sufficient time to capture relevant clinical outcomes.
Key Findings
At baseline, the median LSM was 8.8 kPa, and 33.5% of patients had advanced fibrosis (F3-F4). During the follow-up period, 126 patients (3.6%) developed liver-related events, predominantly hepatic decompensation (123 cases).
The prognostic performance of LSM by VCTE was comparable to histology across multiple predictive metrics:
- The 5-year area under the receiver operating characteristic curve (AUROC) values for predicting LREs were 0.870 for LSM and 0.869 for histology, indicating similarly high accuracy.
- Integrated AUROC and precision-recall curve analyses confirmed this equivalence with values of 0.878 vs. 0.852 and 0.137 vs. 0.068 for LSM and histology, respectively.
- Brier scores, measuring prediction error, were nearly identical (1.389% vs. 1.391%).
- The integrated discrimination improvement index detected no significant difference between modalities.
These similarities persisted across all outcomes examined, including HCC and hepatic decompensation, various time points, and sensitivity analyses adjusting for potential confounders.
Expert Commentary
This study’s robust sample size and long-term follow-up provide compelling evidence supporting the clinical utility of VCTE-derived LSM as a noninvasive prognostic biomarker in MASLD. Given the logistic and patient-related challenges of liver biopsy, a noninvasive tool with comparable accuracy could revolutionize patient management and facilitate broader clinical trial inclusion.
While histology provides valuable insights into inflammation and steatohepatitis, this study underlines that fibrosis staging via liver stiffness captures the essential prognostic element for liver-related clinical outcomes. The concordance in prognostic performance supports increasing reliance on VCTE in routine practice and research settings.
Nonetheless, limitations include the predominantly tertiary care population and potential for unmeasured confounding. It remains essential to consider complementary clinical and laboratory data alongside elastography results. Furthermore, the study did not extensively evaluate emerging imaging or serum biomarkers that may complement or refine risk assessment.
Conclusions
This extensive multicenter study establishes that liver stiffness measurement by vibration-controlled transient elastography has prognostic accuracy comparable to liver biopsy histology for predicting major liver-related events in patients with metabolic dysfunction-associated steatotic liver disease. As a noninvasive, widely accessible modality, VCTE offers a valuable alternative surrogate endpoint in clinical trials and routine management, potentially reducing the need for invasive liver biopsies.
Future research should focus on integrating elastography with other noninvasive biomarkers and refining risk stratification models tailored to diverse clinical settings. The translation of these findings may improve patient care by enabling earlier identification of high-risk MASLD patients and guiding therapeutic interventions.
Funding and Clinical Trials Registration
The study was funded by multiple international research grants and collaborative academic entities involved in MASLD research. Specific funding sources and trial registration details were reported in the original publication.
References
- Zhang Y, Lee HW, Lin H, et al. Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease. Hepatology. 2025;84(1):175-190. PMID: 41452034.
- European Association for the Study of the Liver (EASL) Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2021;75(3):659-689.
- Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
